RENALYTIX PLC – Aim Rule 17 DisclosureRNS Number : 9309R Renalytix PLC 24 August 2026 Renalytix plc (“Renalytix” or the “Company“) AIM Rule 17 Disclosure LONDON and NEW YORK, 24 August 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, provides the following update pursuant to Rule 17 and Schedule…
RENALYTIX PLC – Real World Evidence Study Data PublishedRNS Number : 2622K Renalytix PLC 30 June 2026 Renalytix plc (“Renalytix” or the “Company“) Real world evidence study data published · Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk prognosis, improvements in kidney function, increases in guideline-directed therapy uptake, and measurable reduction in individual patient…
